1. A CD47‐blocking TRAIL fusion protein with dual pro‐phagocytic and pro‐apoptotic anticancer activity. (26th October 2013) Authors: Wiersma, Valerie R.; He, Yuan; Samplonius, Douwe F.; van, Robert J.; Gerssen, Jurjen; Eggleton, Paul; Zhou, Jin; Bremer, Edwin; Helfrich, Wijnand Journal: British journal of haematology Issue: Volume 164:Number 2(2014:Jan.) Page Start: 304 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint. (3rd August 2018) Authors: Koopmans, Iris; Hendriks, Djoke; Samplonius, Douwe F.; van Ginkel, Robert J.; Heskamp, Sandra; Wierstra, Peter J.; Bremer, Edwin; Helfrich, Wijnand Journal: Oncoimmunology Issue: Volume 7:Number 8(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members. Issue 1 (December 2017) Authors: He, Yuan; Bommel, Peter; Samplonius, Douwe; Bremer, Edwin; Helfrich, Wijnand Journal: Scientific reports Issue: Volume 7:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Antibody-based targeting of TNF-ligands for cancer therapy. Issue 2 (January 2015) Authors: Bremer, Edwin Journal: New horizons in translational medicine Issue: Volume 2:Issue 2(2015) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Calreticulin, a therapeutic target?. (1st September 2016) Authors: Eggleton, Paul; Bremer, Edwin; Dudek, Elzbieta; Michalak, Marek Journal: Expert opinion on therapeutic targets Issue: Volume 20:Number 9(2016:Sep.) Page Start: 1137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. (1st February 2018) Authors: van Bommel, Peter E.; He, Yuan; Schepel, Ilona; Hendriks, Mark A. J. M.; Wiersma, Valerie R.; van Ginkel, Robert J.; van Meerten, Tom; Ammatuna, Emanuele; Huls, Gerwin; Samplonius, Douwe F.; Helfrich, Wijnand; Bremer, Edwin Journal: Oncoimmunology Issue: Volume 7:Number 2(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies. Issue 8 (31st July 2022) Authors: Bouwstra, Renée; van Meerten, Tom; Bremer, Edwin Journal: Clinical and translational medicine Issue: Volume 12:Issue 8(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Direct and Indirect Rituximab‐Induced T Cell Depletion: Comment on the Article by Mélet et al. Issue 4 (April 2014) Authors: Eggleton, Paul; Bremer, Edwin Journal: Arthritis & rheumatology Issue: Volume 66:Issue 4(2014) Page Start: 1053 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?. (4th May 2019) Authors: Bouwstra, Renee; van Meerten, Tom; Bremer, Edwin Journal: Molecular & cellular oncology Issue: Volume 6:Number 3(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Harnessing the soil: reshaping the tumor microenvironment towards an antitumor immune state by low‐dose metformin. Issue 8 (20th July 2021) Authors: Lin, Yusheng; Wang, Shuhong; Bremer, Edwin; Zhang, Hao Journal: Cancer communications Issue: Volume 41:Issue 8(2021) Page Start: 637 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗